ZUBSOLV (buprenorphine and naloxone) sublingual tablets (CIII)

ZUBSOLV was first FDA approved in July 2013 and is now offered as an alternative medication for persons with opioid dependence. Similar to other medications in its class it includes both buprenorphine and naloxone but offers some distinct benefits patients may prefer.

  • ZUBSOLV is a medication for adults with opioid dependence
  • ZUBSOLV should be used as part of a complete treatment plan that also includes counseling and behavioral therapy

ZUBSOLV delivers the same concentration of active medication as previously approved buprenorphine/naloxone sublingual (dissolves under the tongue) formulations

But ZUBSOLV is unique as it offers an advanced formulation specifically designed to meet your needs:

  • Preferred menthol flavor
  • Fast dissolve time
  • Smaller tablet
  • Lower dose, same strength

ZUBSOLV gives you the same amount of active medication in the bloodstream with a smaller tablet and lower dose compared with Suboxone

  • Most of the medication in ZUBSOLV tablets gets into the bloodstream, which means a lower dose of ZUBSOLV is similar to a higher dose of Suboxone

Fast dissolve time

  • ZUBSOLV dissolved significantly faster than Suboxone sublingual (under the tongue) tablets
  • Median dissolve time for ZUBSOLV 5.7-mg/1.4-mg tablet was 5 minutes vs 12.5 minutes for Suboxone 8-mg/2-mg tablet
  • In a separate study, the median dissolve time was similar for both ZUBSOLV 5.7-mg/1.4-mg tablet and Suboxone 8-mg/2-mg film

Visit Zubsolv’s website to learn more

Skip to content